MONDAY, NOVEMBER 20, 2017

Single pediatric influenza vaccine dose provides protection

According to a study by researchers at the Institut National de Santé Publique du Québec in Québec City, a single pediatric dose of AS03-adjuvanted vaccine against pandemic influenza A/H1N1 conferred substantial protection against influenza-related hospitalization.

The vaccine was effect in children aged six months to nine years and led to protection beginning 10 days after vaccination. The study was published online Monday in Pediatrics and the lead author was Rodica Gilca, Doctors Lounge reports.

Gilca and her colleagues analyzed the effectiveness of a single pediatric dose of AS03-adjuvanted vaccine for preventing confirmed pH1N1-related hospitalization in children aged six months to nine years in 2009. The control group was non-hospitalized children with pH1N1 and was matched with age and region of residence to children hospitalized for pH1N1 infection. The vaccination status of the participants was assessed in relation to the date of the onset of illness.

The researchers found that a single pediatric dose of vaccine administered 14 days or more before illness onset conferred overall vaccine effectiveness of 85 percent. The effectiveness varied with age, Doctors Lounge reports. Immunization at 10 days or more before illness onset conferred an overall vaccine effectiveness of 80 percent.

"A single pediatric dose of the AS03-adjuvanted pH1N1 vaccine given to children aged six months to nine years is highly protective against hospitalization," the authors wrote, according to Doctors Lounge.

Several authors disclosed financial relationships with vaccine manufacturers.